European Patent Office

T 0569/21 (Combination treatment for cystic fibrosis / VERTEX) vom 07.12.2023

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2023:T056921.20231207
Datum der Entscheidung
7. Dezember 2023
Aktenzeichen
T 0569/21
Antrag auf Überprüfung von
-
Anmeldenummer
15721912.2
Verfahrenssprache
Englisch
Verteilung
Nicht verteilt (D)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
Name des Antragstellers
Vertex Pharmaceuticals Incorporated
Name des Einsprechenden
Generics (U.K.) Limited
Kammer
3.3.04
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Schlagwörter
Main request - amendments - added subject-matter (no)
Main request - sufficiency of disclosure (yes)
Main request - novelty (yes)
Inventive step - (yes)
Inventive step - unexpected improvement shown
Objection of lack of inventive step - not substantiated - admitted (no)
Late-filed request - circumstances of appeal case justify admittance (yes)
Orientierungssatz
-
Zitierte Akten
G 0002/21T 0305/87
Zitierende Akten
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent based on the following documents:

claims 1 to 21 of the main request submitted during the oral proceedings as new auxiliary request 1; the description and drawings possibly to be adapted thereto.